There is considerable interest in identifying small, drug-like compounds that slow aging in multiple species, particularly in mammals. Such compounds may prove to be useful in treating and retarding age-related disease in humans. Just as invertebrate models have been essential in helping us understand the genetic pathways that control aging, these model organisms are also proving valuable in discovering chemical compounds that influence longevity. The nematode Caenorhabditis elegans has numerous advantages for such studies including its short lifespan and has been exploited by a number of investigators to find compounds that impact aging. Here, we summarize the progress being made in identifying compounds that extend the lifespan of invertebrates, and introduce the challenges we face in translating this research into human therapies.
Introduction
Aging is the single largest risk factor for chronic disease in developed countries and is consequently responsible for an enormous social and economic burden. The development of therapies or preventive measures aimed at reducing or delaying age-related disease must be a priority for the biomedical community. However, the traditional models of drug discovery are failing when it comes to the major chronic diseases of the elderly. The disappointing outcomes of dozens of phase III clinical trials in Alzheimer's disease and Parkinson's disease, among others, suggest a general failure in our understanding of the mechanisms at play (Sperling et al., 2011) . This has led some commentators to ask whether targeting aging mechanisms might lead to better outcomes.
Novel compounds that slow aging are highly sought after due to their potential for treating age related diseases. Here, we argue that recent growth of a new subfield, the chemical biology of aging, will lead to the identification of candidate compounds and mechanistic insights that will ultimately propel forward treatments of age related diseases. While identifying compounds that slow the aging of mammals is undoubtedly more relevant for human drug development, the prohibitive cost of mouse aging studies, make it extremely unlikely that large scale chemical screens will be carried out in mice. Basic research in more cost effective model systems is therefore a critical starting point for identifying such * Corresponding authors. compounds and elucidating their mechanism(s) of action. Cell culture and invertebrate model organisms provide opportunities to screen hundreds of thousands of chemical compounds in an efficient manner. Moreover, once candidate compounds are identified, the strengths of these model systems in molecular genetics, allows for rapid elucidation of the genetic pathways being targeted by these compounds.
In this review, we summarize the contribution of invertebrate models to our understanding of the pharmacology of aging, and speculate on the directions the field is headed in the imminent future. We will almost exclusively focus on Caenorhabditis elegans research, since most of the chemical biology of aging studies to date, have been conducted in the nematode. However, we will also discuss a limited number of pharmacological aging studies undertaken in the fruit fly Drosophila melanogaster.
General consideration when conducting experiments to identify lifespan extending compounds

High-throughput chemical screens vs. candidate based approaches
In screening compounds for biological activity, investigators are often drawn to the idea of examining a wide range of chemical structures using high-throughput screens. Due to the prohibitive cost, labor and (for aging studies) the relatively long lifespan of the current vertebrate models, they are impractical for large scale chemical screens, particularly mice. Therefore, researchers have turned to in vitro and invertebrate models to conduct such large
